Hopefully it's a major Licensing deal ahead of US Medicare rebate. PIQ has been in discussions for sometime now in the US, it could be a show of confidence that FDA will approve a rebate. I think a ruling is expected by year end.
An upfront licensing fee offset against future royalties would be an ideal scenario, no need to raise capital in the short term at least.
With a potential endometriosis blood test in the pipeline whoever is licensed in the US would have an established working relationship this could be seen as added value to the deal.
Hopefully it's a major Licensing deal ahead of US Medicare...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $60.56M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.0¢ | $51.50K | 144.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18336 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 9405 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |